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Abstract
Background: Glycogen storage disease (GSD) is a rare inborn error of the synthesis or degradation of glycogen
metabolism. GSD1, the most common type of GSD, is categorized into GSD1a and GSD1b which caused by the
deficiency of glucose-6-phosphatase (G6PC) and glucose-6-phosphate transporter (SLC37A4), respectively. The high
rates of consanguineous marriages in Iran provide a desirable context to facilitate finding the homozygous
pathogenic mutations. This study designates to evaluate the clinical and genetic characteristics of patients with
GSD1b to assess the possible genotype-phenotype correlation.
Results: Autozygosity mapping was performed on nineteen GSD suspected families to suggest the causative loci.
The mapping was done using two panels of short tandem repeat (STR) markers linked to the corresponding genes.
The patients with autozygous haplotype block for the markers flanking the genes were selected for direct
sequencing. Six patients showed autozygosity in the candidate markers for SLC37A4. Three causative variants were
detected. The recurrent mutation of c.1042_1043delCT (p.Leu348Valfs*53) and a novel missense mutation of
c.365G > A (p.G122E) in the homozygous state were identified in the SLC37A4. In silico analysis was performed to
predict the pathogenicity of the variants. A novel whole SLC37A4 gene deletion using long-range PCR and
sequencing was confirmed as well. Severe and moderate neutropenia was observed in patients with frameshift and
missense variants, respectively. The sibling with the whole gene deletion has shown both severe neutropenia and
leukopenia.
Conclusions: The results showed that the hematological findings may have an appropriate correlation with the
genotype findings. However, for a definite genotype-phenotype correlation, specifically for the clinical and
biochemical phenotype, further studies with larger sample sizes are needed.
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Background
Glycogen storage diseases (GSDs) comprise a heteroge-
neous group of rare inborn errors of metabolism disor-
ders caused by deficiency of the specific enzymes in
glycogen degradation and synthesis. Depending on the
impaired enzyme and affected organ, GSDs are classified
into over 10 types. GSD1 is the most common liver im-
pairment with an overall incidence of about 1:100,000
live births. It is categorized into 1a (GSD1a) and 1b
(GSD1b). GSD1a is the more frequent type responsible
for > 80% of GSD 1 patients [1] while GSD1b is esti-
mated to represent ~ 20% of cases [2].
Deficiency in glucose-6-phosphatase-α (G6Pase-α)/glu-
cose-6-phosphate transporter (G6PT) complexes causes
GSD1. This complex has a key role in maintaining glu-
cose homeostasis through glycogenolysis and gluconeo-
genesis in liver, kidney, and intestine. G6Pase-α which is
encoded by the G6PC gene catalyzes the hydrolysis of
glucose-6-phosphate (G6P) to glucose and phosphate.
The products will be transported into the lumen of the
endoplasmic reticulum from the cytoplasm by G6PT
(encoded by the SLC37A4 gene) [2, 3]. GSD1a disease is
caused by the deficiency of the G6Pase-α which is lo-
cated at the endoplasmic reticulum membrane. GSD1a
and GSD1b patients represent similar metabolic pheno-
types such as hypoglycemia, hepatomegaly, lactic acide-
mia, hyperlipidemia, and nephromegaly. Additionally,
GSD 1b patients exhibit neutropenia and impaired neu-
trophil function; resulting in recurrent bacterial infec-
tions, inflammatory bowel disease (IBD), and aphthous
stomatitis [4]. Nevertheless, not all GSD 1b patients
manifest neutropenia, it may cause by either one or
more modifiers on G6PT function or SLC37A4 muta-
tions with residual transport activity [4, 5].
The diagnosis of GSD1 is based on the clinical
symptoms, biochemical parameters, and G6Pase activ-
ity on liver biopsy tissues which is an invasive pro-
cedure. The clinical manifestations are not always
useful to differentiate between GSD types 1a and 1b
patients [6]. The definitive diagnosis of the disease is
established by molecular analysis of G6PC and
SLC37A4.
The estimated rate of consanguineous marriages in
Iran is about 38.6% [7] which provides an appropriate
context for autozygosity mapping. This powerful tool
helps us to quickly identify the possible defective gene
flagged by autozygous blocks. Accordingly, in this
project we identified candidate short tandem repeat
(STR) markers flanking G6PC and SLC37A4 with ac-
ceptable heterozygosity in the selected population.
Suitable families who showed autozygosity for the
markers flanking SLC37A4 were selected for add-
itional molecular genetics investigations. The aim of
this study is to evaluate the clinical and genetic
characteristics of patients in order to assess the pos-
sible genotype-phenotype correlation.
Material and methods
Patients
Patients were recruited from the Children Medical
Center Hospital and the Mofid Children’s Hospital in
Tehran, Iran during January 2015–April 2019. Twenty
Iranian patients from 19 unrelated families were in-
vestigated. Inclusion criteria were based upon clinical
presentations of hepatomegaly, “doll face” and bio-
chemical laboratory tests such as hypoglycemia,
hypertriglyceridemia, hypercholesterolemia, hyperlacta-
temia, hyperuricemia, and elevated aspartate amino-
transferase (AST) or alanine transaminase (ALT)
suggestive of GSD.
The other laboratory measurement was cell blood
count including neutrophil count and white blood cell
count (WBC). In addition, patients were selected after
confirmation by histological analysis of liver biopsy. All
patients participating in this study had consanguineous
parents. Genetic counseling was conducted and all sub-
jects and/or their parents signed the consent form. The
Ethical Committee of the Tehran University of Medical
Sciences approved the study.
Molecular genetics studies
Human genomic DNA was isolated from peripheral
leukocytes using Salting out method [8]. To indirectly
find the possible mutated gene, autozygosity mapping
was performed using the proper STR markers flank-
ing SLC37A4 and G6PC genes. Six polymorphic STR
markers linked to these genes were selected using
Tandem Repeat Finder (TRF) and Sequence-based Es-
timation of Repeat Variability (SERV) software [9, 10].
An attempt was made to select markers with the
length of 3–5 nucleotide repeats, high allelic hetero-
geneity and the nearest markers flanking upstream
and downstream of the genes responsible for GSD1.
The heterozygosity of the selected markers was
assessed in 10 random and unrelated individuals. The
selected markers were amplified with specific primers
(the primer sequences are available upon request).
Then the PCR products were analyzed by running on
10.0% polyacrylamide gels and silver nitrate staining.
Then a haplotype map was drawn for each family
(Fig. 1). Then exons and intron-exon boundaries of
the candidate gene were sequenced (the primer
sequences are available upon request) and were com-
pared with the cDNA reference (NM_001164277 and
NM_000151). PCR reaction for sequencing was per-
formed in a total volume of 25 μl which included 8 μl
the Taq 2× Master Mix (Amplicon Company), 1 μl of
each 10 pM primer, 13.5 μl DH2O and 1.5 μl of 50
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ng/μl DNA. Amplifications of all the exons were carried
out under the following program; 95 °C for 5 min, 95 °C
for 30s, 60 °C for 30s, and 72 °C for 40s repeated by 35
thermal cycles using a thermal cycler (Applied Biosystems,
USA) and final step at 72 °C for 5 min. The novel muta-
tions were named according to the nomenclature re-
commendations of the Human Genome Variation Society
(HGVS) (http://www.hgvs.org).
Long-range PCR assay
To identify the presence of whole SLC37A4 gene dele-
tion and to confirm the deletion breakpoint sequences,
three primers (F1, R1, and R2) were designed using Pri-
mer 3 software for two Long-range PCRs and Sanger se-
quencing. The sequences and chromosome position of
these primers were shown in Table 1. In this Long-range
PCR assays, the 25 μl PCR mixture contains 12.5 μl of
Fig. 1 It shows haplotype analysis of the investigated families. a, b & c The affected Childs (P1, P2 & P3) showed autozygosity for STR markers
flanking of SLC37A4 gene which mutation analysis revealed c.1042_1043delCT mutation. d The affected child (P4) showed autozygosity for STR
markers flanking of SLC37A4 gene which mutation analysis revealed c.365G > A mutation. e The affected siblings (P5–1 & P5–2) showed
autozygosity for STR markers flanking of the SLC37A4 gene which mutation analysis revealed a large deletion
Table 1 The primers characteristics and the size of PCR products used for Long-range PCR assays
Name Sequence Chromosome Position (GRCh37) PCR product size
First long-range PCR F1 AGCATCACTACTGTTACTCCTCAC Chr11: 118902469–118902492 8276 bp
R1 GGAGAATGCTGACCCTGATGAC Chr11: 118894217–118894238
Second long-range PCR F1 AGCATCACTACTGTTACTCCTCAC Chr11: 118902469–118902492 2724 bp
R2 ATGTCCATGGATCTCAGAGCTTC Chr11: 118899769–118899791
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LongAmp Taq 2X Master Mix (New England Biolabs),
0.5 μl of each 10 pM primer, 10 μl DH2O and 1.5 μl of
50 ng/μl DNA. The first Long-range PCR assay was car-
ried out under the following program; 94 °C for 30s,
94 °C for 30s, 62 °C for 60s, and 65 °C for 8 min repeated
by 30 amplification cycles and final step at 65 °C for 10
min. The second Long-range PCR assay was performed
with the slightly different program; 94 °C for 30s, 94 °C
for 30s, 62 °C for 50s, and 65 °C for 1.5 min repeated by
30 amplification cycles and final step at 65 °C for 10 min.
The PCR products were run using 0.8% agarose gel
electrophoresis.
In silico assessment of pathogenicity of the novel variants
Pathogenicity of the variants was investigated using sev-
eral criteria: (1) population databases such as 1000 gen-
ome project (1000 GP) (http://browser.1000genomes.
org), dbSNP (http://www.ncbi.nlm.nih.gov/snp), Exome
Aggregation Consortium (ExAC) (http://exac.broadinsti-
tute.org), NHLBI GO Exome Sequencing Project (ESP)
(http://evs.gs.washington. Edu) were investigated to as-
sess allelic frequency of the variant. (2) in addition, Clin-
Var (http:// www.ncbi.nlm.nih.gov/clinvar), HGMD
(http://www.hgmd.org), Ensemble (https://www.ensembl.
org) and recently published articles on PubMed was
searched for previously reported variants. (3) A variety
of in silico tools consisted of PROVEAN [11], PolyPhen-
2 [12], MutationTaster [13], HOPE [14], Combined An-
notation Dependent Depletion (CADD) [15], and DANN
score [16] were used to evaluate the functional effect of
the novel variants on the protein. The multiple tools
such as PhyloP and PhastCons through UCSC genome
browser and GERP were used to investigate the conser-
vation scores [17]. (4) For further confirmation of the
pathogenicity of the variants, segregation analysis of the
parents was performed using direct sequencing. (5) The
identified variants were classified and interpreted ac-
cording to the ACMG-AMP 2015 Standards and Guide-
lines [18] that facilitated by the Varsome tool [19].
Results
Patient phenotypes
The clinical, biochemical, and hematological parameters
of patients with detected causative variants of the
SLC37A4 gene are presented in Table 2. There were sig-
nificant differences in the clinical and biochemical pa-
rameters indicating heterogeneity between these GSD1b
patients. Consanguinity was detected in all cases. Almost
all patients presented hepatomegaly and hypoglycemia.
Also, all patients had recurrent infections including oti-
tis, respiratory tract infection, gingivitis, oral candidiasis,
pharyngitis, periodic aphthous stomatitis. Hematological
findings were different in patients; P1, P2, and P3 with
severe neutropenia, P4 with moderate neutropenia and a
sibling (P5–1 and P5–2) with both severe neutropenia
and leukopenia (leukocyte count and percentage of neu-
trophil cells were shown in Table 2). Anemia was ob-
served in all patients except for P4. The other main
biochemical parameters were hyperlipidemia, hyperlacta-
temia, and elevated AST and ALT levels (four patients
(66%)), hypercholesterolemia (two patients (33%)),
hyperuricemia (three patients (66%)). The clinical infor-
mation collected from the mentioned patients (P5–1 and
P5–2) belongs to the time of disease diagnosis.
P4 showed hypoglycemia and hepatomegaly in the first
year of life. Laboratory examinations showed elevated
triglyceride (TG) concentration and uric acid but liver
transaminases were normal to slightly increased. Devel-
opment, growth and facial appearance were normal.
Liver biopsy showed severe fatty changes (microvesicular
and macrovesicular) and steatosis. The liver was en-
larged with normal echogenicity and both kidneys are
mildly enlarged. Furthermore, she presented clinically
with otitis media, gingivitis, neutropenia (WBC =
7.08*103/μl, Neutrophil count =966) without leukopenia.
Her twin sister had almost similar clinical presentations
such as hypoglycemia and hepatomegaly and presented
steatosis in liver biopsy. However, she suffered from
congenital cataract at the first month of life, growth re-
tardation, epistaxis and elevated creatine phosphokinase
(CPK) (data not available) and finally she died due to
hypoglycemic coma after 1 year without a definite
diagnosis.
Patient P5–1, a 19-year-old girl had suffered from se-
vere neutropenia with leukopenia (WBC = 1.7*103/μl,
Neutrophil count = 289/μl) that in the first days of life
referred to our pediatric clinic with nausea, acidosis,
poor feeding, elevated TG (218mg/dl), hypoglycemia
and hepatomegaly. At sampling date, laboratory examin-
ation revealed normal fasting blood glucose, uric acid,
TG, and liver transaminases. She had recurrent
infectious with otitis, pharyngitis, periodic aphthous sto-
matitis. Other clinical observations were mild hepatos-
plenomegaly, enlarged bilateral kidneys, anemia, and
increased Erythrocyte Sedimentation Rate (ESR). Chest
X-Ray showed bilateral reticular infiltration and de-
creased bone density. The result of liver biopsy revealed
ballooning changes with feathery degeneration and mild
steatosis. She had a brother, patient P5–2, a 9-year old
boy with similar clinical and laboratory manifestations.
He was brought to the pediatric clinic due to seizure at
birth, an elevated level of TG concentration (464 mg/dl)
and moreover, at 4 months, he suffered from severe
metabolic acidosis, lethargy, tachypnea, fever, vomiting,
poor feeding, and hepatomegaly. Also, he experienced
recurrent aphthous stomatitis, neutropenia with
leukopenia (WBC = 2.5*103/μl, Neutrophil count = 570/
μl), increased ESR, anemia and severe osteopenia. He
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was the second child of the consanguineous family with
no family history of GSD.
Molecular analysis of the identified variants
From the twenty studied patients, six showed autozygous
haplotypes for the STR markers flanking the SLC37A4
gene and any patients did not show any autozygosity for
the markers flanking the G6PC gene. Sequence analysis
of the entire and intron/exon boundaries of the
SLC37A4 gene revealed three different mutations in pa-
tients with a homozygous haplotype. Haplotype map was
shown for families with novel mutations in Fig. 1. Three
patients showed two novel mutations (c.365G > A
(p.G122E) and whole SLC37A4 gene deletion) and three
patients presented a recurrent mutation (c.1042_1043del
(p.Leu348Valfs*53)). The recognized mutations in pa-
tients were homozygous and were not present in their
healthy members of the family. Segregation analysis
showed that their parents were heterozygous for the rec-
ognized mutations.
The first novel mutation, c.365G > A (p.G122E) in the 4th
exon
One of the two novel variants, c.365G > A (p.G122E) in
4th exon, was identified in the P4 patient that was
homozygous for this variant. The twin sister died and
her DNA was not available. According to our survey, the
variant was not found in any of the population or disease
databases as mentioned above. In silico predictive tools
showed the deleterious effect on the variant on gene
product (Table 3). The evolutionary tools showed gly-
cine residue at the position 122 of SLC37A4 protein is
highly conserved (PhyloP, PhastCons, and GERP; 4.3
and 1.0 and 5.1, respectively) and multispecies alignment
is shown for this variant in UCSC genome browser
(Fig. 2). As predicted by the HOPE project, the mutant
residue is bigger and less hydrophobic than the wild-
type residue and is negatively charged. According to
Varsome tool, this variant is predicted to be variant of
uncertain significance (VUS) based on these evidences:
(1) The absence of detected variant in any of the popula-
tion databases (PM2). (2) Missense variant in the
SLC37A4 gene that has a low rate of benign missense
variation and in which missense variants are a common
mechanism of GSD1b disease (PP2) and multiple bio-
informatics evidence support a deleterious effect on the
gene or the protein (PP3).
The second novel mutation, SLC37A4 gene deletion
In the sibling (P5–1 and P5–2), a systematic failure to
amplify genomic DNA covering all exons of the SLC37A4
gene directed the possible presence of whole gene deletion
(g.118895235_118901946del6712 (GRCh37)). To confirm
the presence of full-gene deletion and finding the exact
breakpoint site, primer walking with the help of three
primers (F1, R1, and R2) was done (Table 1). For the first
Long-range PCR assay, F1 and R1 primers were designed
flanking regions of the suspected deletion (876 bp up-
stream and 844 bp downstream of the SLC37A4 gene).
Sanger sequencing was performed to identify the exact lo-
cation of the breakpoint site. The results of sequencing
established our prediction and identified the location of
breakpoint precisely at Chr11:118895235–118,901,946
(Fig. 3). It permitted us to determine the exact size of the
deleted region (6712 bp). Gel electrophoresis of this PCR
product revealed homozygote deletion in the sibling and
heterozygote deletion in parents. The size of DNA frag-
ment in siblings was 1564 bp, while the size of the ex-
pected genomic segments without deletion was 8276 bp in
the control sample, and both segments exist in parents as
Table 3 Table caption
Patients P1, P2 and P3 P4 P5-1 & P5-2
Variant Definition Varian name
Protein Change
c.1042_1043delCT
p.Leu348Valfs*53
c.365G>A
G122E
g.118895235_118901946del6712
Chromosome Position
(GRCh37)
Zygosity
Chr11 :118895981_
118895982
Homozygote
Chr11: 118898920
Homozygote
Chr11: 118895235 to chr11:
118901946
Homozygote
In-silico Predictive Tools CADD (Phred Score)
DANN
Polyphen-2
PROVEAN
35(Deleterious)
-
-
-
27.4 (Deleterious)
0.82 (Deleterious)
0.958
(PROBABLYDAMAGING)
2.66 (Deleterious)
-
-
-
-
Population/Disease
Databases
1000 GP
ExAC
GenomAD
ESP
HGMD
Clinvar
-
0.00023
0.00018
0.0003
CD982664
VCV000006926
-
-
-
-
-
-
-
-
-
-
-
-
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expected. To further confirm the presence of deletion, the
second Long-range PCR assay with another set of primers
(F1 and R2) was used to discriminate between cases with
and without deletion. R2 primer was designed around the
4th exon as an internal control. To visually confirm the
mutant and wide type alleles, PCR products were run on
gel electrophoresis and generated a 2724 bp fragment in
parents. There was no amplification in patients bearing
the deletion.
Discussion
GSD1 is the most prevalent hepatic type of Glycogen
storage diseases (GSDs) which comprises a group of
autosomal recessive disorders characterized by the defi-
ciency of the enzymes that regulate the synthesis or deg-
radation of glycogen. GSD1 categorized into two
overlapping forms, 1a and 1b which caused by the defi-
ciency of G6PC and SLC37A4 genes, respectively [1].
The high rate of consanguineous marriage in Iran pro-
poses a high incidence of autosomal recessive disorders.
Since GSD1 is a rather rare disease in Iran and other
populations, only a few studies have been published
regarding the GSD1 mutational spectrum in Iran and
elsewhere [21], so we decided to conduct autozygosity
mapping to quick and indirectly find the mutated gene
in nineteen families suspected to GSD. Haplotype ana-
lysis of the studied families showed six patients with
autozygous haplotype block for the SLC37A4 gene and
no family was autozygous for the markers flanking the
G6PC gene. Subsequently, the sequencing of the
SLC37A4 gene was revealed two novel and one recurrent
mutation in six patients. This is the first study to
summarize the clinical and molecular characteristics of
Iranian patients with GSD Ib.
SLC37A4 deficiencies affect metabolic and myeloid
phenotypes. In metabolic phenotype, in gluconeogenic
organs of liver, kidney, and intestine, SLC37A4 and G6PC
together are required to maintain interprandial blood
glucose homeostasis. In myeloid phenotype, SLC37A4 and
G6PC3 together are required to maintain neutrophil
homeostasis and their deficiency leads to immune defi-
ciency, characterized by neutropenia and neutrophil dys-
function [3]. Previous Studies have shown that GSD-Ib
patients exhibit an increased risk of developing auto-
immune disorders, including IBD, thyroid autoimmunity,
and myasthenia gravis. Melis and colleagues exhibited that
GSD-Ib patients indicated lymphopenia and T cells exhibit
altered glycolysis and impaired peripheral regulatory T cell
function [22]. In previous studies, the most common
mutation was c.1042_1043del (p.Leu348Valfs*53) that has
been recurrently reported in German (32%) populations
and mixed Caucasian (27–31%) [23]. The mentioned
deletion in the 8th exon leads to the deficiency of enzyme
activity which accompanied by severe neutropenia in three
patients in our study (P1, P2, and P3). These three patients
have several hospitalizations due to hypoglycemia and
seizure attacks. In addition to GSD1b common symptoms
(OMIM:232220), P3 suffered from secondary symptoms
such as vision weakness, severe hearing loss, strabismus,
developmental delay and autism-like behaviors that had
not been reported with this disease in previous publica-
tions. These signs may be due to recurrent severe seizures.
Regarding the novel c.365G > A (p.G122E) mutation in
P4 patient, glycine at the transmembrane domain of the
glucose 6-phosphate translocase enzyme is more hydro-
phobic than the mutant residue. This difference in hydro-
phobicity can affect the hydrophobic interactions with the
membrane lipids. Furthermore, glycine is the most flexible
of all residues. This flexibility might be necessary for the
Fig. 2 Multispecies alignment for the identified variant in P4 patient: c.365G > A, p.G122E. The panel from the UCSC genome
browser (https://genome.ucsc.edu/cgi-bin/)
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protein’s function [14]. Mutation of this glycine can abol-
ish this function and coincidently, the torsion angles of
this residue are incorrect. In silico analysis tools were con-
sistent in predicting that this variant may impair protein
function and this substitution can change the enzyme
conformation. The hematological findings in this patient
showed moderate neutropenia in contrast to P1, P2, and
P3 patients (frameshift variant) with severe neutropenia.
Fig. 3 Long-range PCR and sequencing showed the full-gene deletion of SLC37A4 in the siblings (P5–1 and P5–2) with GSD1b. a the
gene transcript image (was taken from Genome Data Viewer in NCBI) and the orientation of the designed primers across upstream and
downstream breakpoint. The black arrows indicate the position of primers used in Long-range PCR. The length of the genomic segment
for each set of primers (F1&R1 and F1&R2) was shown. b Sanger sequencing result of the breakpoint site and flanking region. Two boxes
above the sequencing result indicate the sequences across upstream and downstream breakpoint. In Sanger sequencing result, the blue
arrow shows the breakpoint and a 6712 bp sequence deletion on chr11 of the human reference genome (GRCh37). c Gel electrophoresis
of the PCR product. i) Results of the first long-range PCR (PCR with F1 and R1 primers) are presented in the left which shows this
segment in the siblings, parents and control samples. Lane 1 contains a 10 kb ladder, lane 2 and 3 contains the products of deleted
allele, lane 3 and 4 contains the products of both the deleted allele and the wide type. Lane 5 contains the wide-type allele. ii) Results
of the second long-range PCR (PCR with F1 and R2) are presented in the right which shows this segment in two siblings, parents and
control samples. Lane 1 contains a 10 kb ladder, lane 2 contains NTC, Lane 3, 4 and 5 contains a 2724 bp fragment without deletion and
lane 6 and 7 contains no amplification. All lanes (except lane 2) include a ~ 700 bp internal control (Exon 5 of G6PC gene). The products
of deleted allele, (1564 bp); the products of wide-type allele, (8276 bp); M, mother; F, father; CT, control sample
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The CADD score, which has high sensitivity to predict
molecular pathogenicity of variants, was 27 and 35 in mis-
sense variant (p.G122E) and frameshift variant (p.Leu348-
Valfs*53), respectively. Since the higher values of CADD
score predict more severe effect, it may explain the pro-
nounced hematological finding in P1, P2, and P3 patients
in comparison to P4.
The second novel mutation, whole SLC37A4 gene de-
letion, was identified in a sibling (P5–1 and P5–2). The
homozygote 6.7 kb deletion which spans near the entire
SLC37A4 gene can lead to the complete loss of function
of both alleles. Therefore, G6PT protein will not be pro-
duced. To date, 116 mutations were identified for
SLC37A4 gene (http://www.hgmd.org) including 86 sub-
stitutions and 30 small/gross deletion and insertions. To
the best of our knowledge, this is the first report of
whole SLC37A4 gene deletion. Here, the siblings (P5–1
and P5–2) had anemia, leucopenia, and severe
neutropenia with increased lymphocyte counts. These
hematological findings suggest a correlation between
entire SLC37A4 gene deletion and severe myeloid problems
in GSD-Ib.
However, in previous studies, no correlation was re-
ported between individual mutations and present/ab-
sence of neutropenia, bacterial infections, and other
complications [24–26]. Recently, one study by Sarajlija A
et al., revealed some specific mutations in SLC37A4 have
an impact on the severity of neutropenia and the cap-
acity of increasing neutrophil count in serious bacterial
infections (SBI) [27]. It is worth to mention that all
GSD1b patients did not have neutropenia and some of
them may suffer from cyclic neutropenia [5]. This
phenotypic variability of GSD 1b might suggest contri-
bution of one or several other factors (ie., as modifier
genes) in phenotype disease, which could change
“simple” Mendelian disorders into complex traits [28].
Conclusions
Clinical and biochemical parameters were different in
the GSD1b patients. Therefore, the strict genotype-
phenotype correlation couldn’t be demonstrated based
on this data. However, hematological findings revealed a
correlation between causative mutations and myeloid
phenotypes. P1, P2, and P3 with frameshift variant
(p.Leu348Valfs*53) had severe neutropenia. P4 with a
missense mutation (p.G122E) showed moderate neutro-
penia. The sibling (P5–1 and P5–2) with whole SLC37A4
deletion represented both severe neutropenia and
leukopenia. This large deletion was accompanied by
severe impairment of myeloid cells. But establishing a
definitive genotype-phenotype correlation would needs
more studies with larger sample sizes. Since GSD is a
group of clinically and genetically heterogeneous dis-
orders, it is recommended to use whole-exome sequencing
(WES) for the detection of causative mutations in families
with no autozygous haplotype block for the markers flank-
ing the G6PC gene.
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